RNS Number:1963U
GeneMedix PLC
14 January 2004


                                                              14th January 2004

                                 GENEMEDIX PLC

                    GeneMedix appoints US Investment Bankers

GeneMedix plc ("GeneMedix" or "the Company"), the UK biopharmaceutical company
with operations in Europe and Asia and with joint London and Singapore Stock
Exchange listings, today announces that it has appointed the New York based
Investment Bankers, Global Markets Capital Group, LLC, to act as its strategic
and corporate advisors in the US. GeneMedix is involved in the development and
manufacture of generic and second-generation versions of therapeutic proteins
using recombinant DNA technology and novel cell culture.

Global Markets Capital Group will assist GeneMedix to develop its corporate
activities and target strategic US merger and acquisition initiatives. This will
be supported by a programme of accessing the US capital markets with a view to
increasing shareholder value, broadening GeneMedix's shareholder base and
improving the Company's financial position.

Mr Mark Saunders, President of Global Markets Capital Group, stated:
"With over a quarter of all new drugs approved since 2000 classed as 
biopharmaceuticals,approximately 500 candidate biopharmaceuticals currently
undergoing clinical evaluation, and pipelines in pharmaceutical companies 
appearing to be under increasing pressure, we expect to see sustained and 
strong growth within the biogenerics sector. We believe that GeneMedix is well 
positioned to take advantage of these opportunities."

Commenting on the appointment, Paul Edwards, Chief Executive Officer of 
GeneMedix plc said:
"We have selected Global Markets Capital due to their sector expertise and US
contacts. The recent debate in the USA regarding the route for licensing
biogenerics has heightened the profile of the sector and we therefore feel the
time is right for GeneMedix to look at strategic opportunities in the USA and
to position itself to access this significant market as it opens up."

Editors' Note

About GeneMedix
GeneMedix is a UK based biopharmaceutical company focused on the development of
biogenerics, or generic versions of currently marketed biopharmaceutical
therapeutics, including erythropoietin (EPO) for the treatment of anaemia,
recombinant insulin for the treatment of diabetes, and interferon alfa for the
treatment of hepatitis C and hepatitis B.

About Global Markets Capital Group
Global Markets Capital Group, LLC is an independent investment banking firm
providing innovative strategic advisory services and mergers and acquisitions
expertise globally to public and private companies. Through its advisory roles
and its network of global companies active in Europe, Asia, Australia and the
US, the firm has assisted numerous international life sciences and emerging
technology companies in achieving their strategic goals.

ENQUIRIES:

GeneMedix plc                                     Tel: 01638 663 320
Paul Edwards, Chief Executive Officer

Global Markets Capital Group, LLC                 Tel: 01 212 808 9700
Mark Saunders, President

Bankside Consultants                              Tel: 0207 444 4140
Michael Padley/Susan Scott

Further copies are available from the Group's head office - Rosalind Franklin
House, Fordham Road, Newmarket, Suffolk, CB8 7XN




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCGUUPUGUPCGMW